Cheyne Capital Management UK LLP boosted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 100.0% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 200,000 shares of the biotechnology company’s stock after buying an additional 100,000 shares during the period. Cheyne Capital Management UK LLP’s holdings in BioCryst Pharmaceuticals were worth $1,526,000 at the end of the most recent reporting period.
Other hedge funds also recently made changes to their positions in the company. Warren Averett Asset Management LLC acquired a new stake in BioCryst Pharmaceuticals in the 3rd quarter valued at $171,000. Paloma Partners Management Co acquired a new stake in BioCryst Pharmaceuticals in the 2nd quarter valued at $174,000. Wells Fargo & Company MN boosted its stake in BioCryst Pharmaceuticals by 29.3% in the 1st quarter. Wells Fargo & Company MN now owns 68,052 shares of the biotechnology company’s stock valued at $324,000 after buying an additional 15,403 shares in the last quarter. Spark Investment Management LLC acquired a new stake in BioCryst Pharmaceuticals in the 2nd quarter valued at $344,000. Finally, State of Wisconsin Investment Board boosted its stake in BioCryst Pharmaceuticals by 79.1% in the 2nd quarter. State of Wisconsin Investment Board now owns 100,300 shares of the biotechnology company’s stock valued at $575,000 after buying an additional 44,300 shares in the last quarter. 79.82% of the stock is currently owned by institutional investors and hedge funds.
Several analysts recently commented on the company. ValuEngine raised BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, August 8th. BidaskClub lowered BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, July 28th. Royal Bank of Canada reissued a “buy” rating and issued a $9.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 7th. Zacks Investment Research lowered BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 15th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $8.50 price objective on shares of BioCryst Pharmaceuticals in a research note on Thursday, August 9th. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $9.89.
In other BioCryst Pharmaceuticals news, insider Thomas R. Staab II sold 9,850 shares of the business’s stock in a transaction on Wednesday, October 3rd. The stock was sold at an average price of $7.24, for a total value of $71,314.00. Following the transaction, the insider now owns 140,633 shares of the company’s stock, valued at $1,018,182.92. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Thomas R. Staab II sold 10,856 shares of the business’s stock in a transaction on Friday, November 2nd. The stock was sold at an average price of $7.84, for a total value of $85,111.04. Following the completion of the transaction, the chief financial officer now directly owns 144,739 shares in the company, valued at approximately $1,134,753.76. The disclosure for this sale can be found here. In the last three months, insiders sold 88,000 shares of company stock worth $631,613. Insiders own 4.50% of the company’s stock.
BioCryst Pharmaceuticals stock opened at $7.77 on Wednesday. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.25 and a quick ratio of 1.25. BioCryst Pharmaceuticals, Inc. has a 52 week low of $4.25 and a 52 week high of $8.13.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.03). BioCryst Pharmaceuticals had a negative return on equity of 107.85% and a negative net margin of 270.95%. Research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.87 earnings per share for the current fiscal year.
WARNING: “Cheyne Capital Management UK LLP Grows Stake in BioCryst Pharmaceuticals, Inc. (BCRX)” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/11/07/cheyne-capital-management-uk-llp-grows-stake-in-biocryst-pharmaceuticals-inc-bcrx.html.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.
Featured Story: What is the NASDAQ?
Want to see what other hedge funds are holding BCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX).
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.